 AUSTIN, Texas, July 14, 2021 PRNewswire -- Aeglea BioTherapeutics, Inc. NASDAQ: AGLE, a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the publication of 20 week data from the Phase 12 clinical trial of pegzilarginase for the treatment of Arginase 1 Deficiency ARG1-D, a rare, progressive and devastating disease characterized by high levels of the amino acid arginine. Pegzilarginase is a novel, recombinant human arginase 1 enzyme designed to lower levels of arginine that is also being investigated in PEACE, an ongoing Phase 3 pivotal trial for the treatment of ARG1-D. 